Podcast appearances and mentions of david cleevely

In the second part of our conversation with David Cleevely, we talk about the Cambridge Cluster, the vital work with government and on policy, and the phenomena of serendipity and paying it forward.David has been instrumental in the Cambridge Cluster for decades, with the founding of groups like Cambridge Network and Cambridge Wireless; creating a vision for Cambridge (a few times); the importance of marketing and having a logo; and keeping Cambridge competitive.A charitable contributor, David firmly believes that if you make some money, you should give back to the community – something Sara Allen at The Cambridge Pledge will be delighted to hear. And we hear about David's pivotal role at Raspberry Pi and the eight years from formulating a plan to a flotation.We talk about why an active involvement in public policy and government liaison is vital, and how entrepreneurs can help to fill gaps and stop us sleepwalking into growth challenges – locally and globally.And we finish with a discussion on serendipity – the approach that will determine your path by making chance encounters happen. Tune in for a future episode when we'll cover David's Book – ‘Serendipity – it doesn't happen by accident'.Produced by Cambridge TV Hosted on Acast. See acast.com/privacy for more information.

We talk with David Cleevely – telecoms, wireless and technology expert, a serial entrepreneur, investor in 55 companies, and an adviser to Government on both a national and local level. David is a Fellow of the Institution of Engineering and Technology, a Fellow of the Royal Academy of Engineering, and last but by no means least, awarded a CBE, for services to technology and innovation. As an active and respected businessman, David vigorously promotes networking, collaboration and the City of Cambridge. The episode starts with David giving his views on the 2024 UK budget announcement which included providing “funding for Cambridge to help it reach its growth potential”.We then take a journey into David's education, career, and entrepreneurial journey including many of the investments he has made and been involved in. What you will hear as a continuous thread - and what we'll talk about more in Part 2 - is how serendipity shapes careers.Produced by Cambridge TV Hosted on Acast. See acast.com/privacy for more information.

Jonathan Milner's second Invested Investor podcast details his experience as Cambridge Angel. Since he began in 2002 he has invested in forty different companies, very often leading deals as well. In this episode he shares his most important tips learned from an extensive entrepreneurial and investing history: from shouldering the burden of turning around a company in dire straits, to simplifying the decision of who to invest in.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Cambridge Angels - a leading UK business angel network with international connections. Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. SyndicateRoom - connecting ambitious investors with the country's most trailblazing companies. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. Milner Centre for Evolution - a unique, cross-faculty research centre atthe University of Bath bridging biology, health, and education. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. In 2011, he founded and ran Martlet: a Corporate VC, investing (currently £10M) from the balance sheet of Marshall, a £2.5bn revenue Cambridge engineering company. He is a fellow in Entrepreneurship at the Cambridge Judge Business School and is on the investment committee of the UK Angel Co-fund. He has also had 16 years' experience as chair, treasurer and trustee of the boards of seven charities. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/entrepreneurship-and-leadership

Jonathan Milner's second Invested Investor podcast details his experience as Cambridge Angel. Since he began in 2002 he has invested in forty different companies, very often leading deals as well. In this episode he shares his most important tips learned from an extensive entrepreneurial and investing history: from shouldering the burden of turning around a company in dire straits, to simplifying the decision of who to invest in.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Cambridge Angels - a leading UK business angel network with international connections. Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. SyndicateRoom - connecting ambitious investors with the country's most trailblazing companies. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. Milner Centre for Evolution - a unique, cross-faculty research centre atthe University of Bath bridging biology, health, and education. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. In 2011, he founded and ran Martlet: a Corporate VC, investing (currently £10M) from the balance sheet of Marshall, a £2.5bn revenue Cambridge engineering company. He is a fellow in Entrepreneurship at the Cambridge Judge Business School and is on the investment committee of the UK Angel Co-fund. He has also had 16 years' experience as chair, treasurer and trustee of the boards of seven charities. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jonathan Milner's second Invested Investor podcast details his experience as Cambridge Angel. Since he began in 2002 he has invested in forty different companies, very often leading deals as well. In this episode he shares his most important tips learned from an extensive entrepreneurial and investing history: from shouldering the burden of turning around a company in dire straits, to simplifying the decision of who to invest in.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Cambridge Angels - a leading UK business angel network with international connections. Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. SyndicateRoom - connecting ambitious investors with the country's most trailblazing companies. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. Milner Centre for Evolution - a unique, cross-faculty research centre atthe University of Bath bridging biology, health, and education. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. In 2011, he founded and ran Martlet: a Corporate VC, investing (currently £10M) from the balance sheet of Marshall, a £2.5bn revenue Cambridge engineering company. He is a fellow in Entrepreneurship at the Cambridge Judge Business School and is on the investment committee of the UK Angel Co-fund. He has also had 16 years' experience as chair, treasurer and trustee of the boards of seven charities. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Jonathan Milner was working as a postdoc in a Cambridge oncology lab when he was struck by an 'entrepreneurial seizure'. Inspired by his father, an engineer who ran a small company, he set up a venture to manufacture antibodies for biology research. Having come close to bankruptcy, Abcam is now worth £2.3 billion and renowned for its positive company culture. In this podcast, the first of two podcasts featuring Jonathan Milner, he takes us through this journey, and explains how lessons learned - as well as a single bucket of ice - turned a failing company into a world leader.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. 18 JULY 2018COMMENT The NBN Entrepreneurship and Leadership podcast aims to educate and entertain, sharing insights based on the stories of carefully selected guests - entrepreneurs and leaders - in the atmosphere of an informal conversation. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/entrepreneurship-and-leadership

Jonathan Milner was working as a postdoc in a Cambridge oncology lab when he was struck by an 'entrepreneurial seizure'. Inspired by his father, an engineer who ran a small company, he set up a venture to manufacture antibodies for biology research. Having come close to bankruptcy, Abcam is now worth £2.3 billion and renowned for its positive company culture. In this podcast, the first of two podcasts featuring Jonathan Milner, he takes us through this journey, and explains how lessons learned - as well as a single bucket of ice - turned a failing company into a world leader.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. 18 JULY 2018COMMENT The NBN Entrepreneurship and Leadership podcast aims to educate and entertain, sharing insights based on the stories of carefully selected guests - entrepreneurs and leaders - in the atmosphere of an informal conversation. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jonathan Milner was working as a postdoc in a Cambridge oncology lab when he was struck by an 'entrepreneurial seizure'. Inspired by his father, an engineer who ran a small company, he set up a venture to manufacture antibodies for biology research. Having come close to bankruptcy, Abcam is now worth £2.3 billion and renowned for its positive company culture. In this podcast, the first of two podcasts featuring Jonathan Milner, he takes us through this journey, and explains how lessons learned - as well as a single bucket of ice - turned a failing company into a world leader.  To read the podcast transcription please CLICK HERE - Powered by Speechmatics Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a postdoctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath. Produced by Mark Cotton, Twitter. Podcast links: Abcam - assay kits, reagents, and antibodies. An innovator in reagents and tools, they provide the research and clinical communities with tools and scientific support. The Milner Therapeutics Institute - at the University of Cambridge is dedicated to the conversion of groundbreaking science into therapies. 18 JULY 2018COMMENT The NBN Entrepreneurship and Leadership podcast aims to educate and entertain, sharing insights based on the stories of carefully selected guests - entrepreneurs and leaders - in the atmosphere of an informal conversation. About Peter Cowley Peter Cowley, a Cambridge university technology graduate, founded and ran over a dozen businesses in technology and property over the last 40 years. He has built up a portfolio of 75 angel investments with nine good exits (including one that is 107X his investment and returned all the cash he has invested) and thirteen failures. He is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Business Angels and was UK Angel of the Year 2014. He has mentored hundreds of entrepreneurs and is on the board of nine startups. With his son, Alan, Peter is sharing his and others' experience and anecdotes in order to educate angels and entrepreneurs via The Invested Investor which publishes two books and 75+ podcasts. A selection of Invested Investor podcasts are republished here on the Entrepreneurship and Leadership channel on the NBN. This is one of them. Peter is a public speaker on entrepreneurship and angel investing throughout the world. Linkedin Peter's webpage. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this episode, we are joined by Dr. David Cleevely CBE, a serial entrepreneur and investor. In this conversation, we explore a range of topics including: How David's companies have pivoted due to the pandemic. Why serendipity has marked David's life. Why meaningful relationships are a major key to success and maintaining a network. Taking risks when you are young and can see trends. David Cleevely, CBE, FREng, FIET is a British serial entrepreneur and international telecoms expert who has built and advised many companies, principally in Cambridge, UK. He has founded many companies and networking organisations including Abcam (one of Cambridge's 17 ‘Unicorns') and Cambridge Angels (which last year partnered in investing over $100m in startups and follow-ups). Find out more about David Cleevely: Cleevely.com Twitter @DavidCleevely Episode Summary: Introduction to David Cleevely (01:01), When do you know when to commit to an idea/investment? (03:00), What pivots have your companies made due to the pandemic? (04:33), How Bocca di Lupo (David's restaurant in London) pivoted during the lockdown (09:35), How has managing all your companies remotely been? (12:11), The advice you'd give to the younger generation (14:16), What to do in your 20s (19:21), Skill-building when you are young (21:06), How are you working with you children with investing (24:38), Do you see yourself shifting to a more passive investor in the future? (29:55), Serendipity and being intentional with your decisions (32:22), Outro (37:04). Twitter: @FinancialSon Email: financialfatherandson@gmail.com

Hacking internet-enabled cars About 40% of cars in the US are connected to the internet. While this enables many useful functions, it also makes them vulnerable to hacks. As all the electronics systems within the car are connected, hackers could take full control of the vehicle. Skanda Vivek tells Gareth how this is possible, and what would happen if a large number of cars were hacked at the same time. Covid-19 treatment trials in AI It is possible to do drug trials in vitro and in vivo – but what about simulating them? The Cambridge-based company AI VIVO uses machine learning and AI to model diseased cells and their potential treatments. For Covid-19, they screened 90,000 different compounds to find out which drugs could be effective against the virus. Could this be a new way to discover drug treatments? Gareth speaks to David Cleevely to find out how it works. Mobile phone rain forecast for farmers Farmers with small holdings in developing countries often do not benefit from new technologies, but a tech project in Pakistan has managed to help drastically reduce their water consumption. Farmers receive text messages about when it is going to rain and whether they should irrigate their crops, generating an average of 40% in water savings. Roland Pease has been finding out more. The programme is presented by Gareth Mitchell with expert commentary from Bill Thompson. (Image: Traffic jam on multilane road. Credit: iStock / Getty Images Plus) Studio Manager: Duncan Hannant Producer: Alex Mansfield

David Cleevely continues his vibrant story in part two of his Invested Investor podcast.  David begins by discussing his reasons for setting up Cambridge Angels in 2001 and why his main focus now lies with his impressive investment portfolio. David co-founded Cambridge Wireless in 2001 and 3Way Networks acquired by Airvana in 2007, in the same year he co-founded and became Chairman of CRFS. David has a wealth of experience and insight to share including his links with the Centre for Science and Policy, the Cambridge Science Centre and the Raspberry Pi foundation before entertaining us with his take on the restaurant business and his successes, Bocca di Lupo and Gelupo. David has recently been recognised as “Icon of the Year” a Barclays award which celebrates the positive ways that entrepreneurs can change an industry, the economy and society. Picture from Road.cc (https://road.cc/content/news/100293-top-entrepreneur-says-cambridge-should-spend-more-cycling)

David Cleevely, Chair of the Raspberry Pi Foundation and co-founder of Cambridge Angels joins the Invested Investor podcast this week with an impressive story. David shares his early career highlights with us in part one of his fascinating journey. In the mid 70’s, David tells us he “cut his teeth” within PostOffice Telecommunications and how this experience taught him to think ahead, which influenced his subject choice for his phD at Cambridge during the 80’s. He also shares with us his time at the Economist newspaper group within the intelligence unit. David recalls how he went on to found Analysys which became the “go to” telecommunications consultancy of the time and his work with the European Commission. David talks about co-founding Cambridge Network, Cambridge Wireless and the biotech company Abcam, before finishing by touching on his consultancy for communications within the Department of Defence.

Jonathan Milner's second Invested Investor podcast details his experience as a Cambridge Angel. Since he began in 2002 he has invested in forty different companies, very often leading deals as well. In this episode he shares his most important tips learned from an extensive entrepreneurial and investing history: from shouldering the burden of turning around a company in dire straits, to simplifying the decision of who to invest in.  Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath.

Jonathan Milner was working as a postdoc in a Cambridge oncology lab when he was struck by an 'entrepreneurial seizure'. Inspired by his father, an engineer who ran a small company, he set up a venture to manufacture antibodies for biology research. Having come close to bankruptcy, Abcam is now worth £2.3 billion and renowned for its positive company culture. In this podcast, the first of two podcasts featuring Jonathan Milner, he takes us through this journey, and explains how lessons learned - as well as a single bucket of ice - turned a failing company into a world leader. Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange. Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is also a non-executive director of Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath.

Dr David Cleevely knows a thing or two about building businesses. A serial entrepreneur and investor, he has worked at the heart of the Cambridge Cluster on numerous ventures including telecoms consultancy Analysys, web based antibody company Abcam (ABC.L); and G femto base station company, 3WayNetworks. Abcam, which he co-founded in 1998 and was Chairman of until 2009, currently has a $1.5bn valuation - not bad for a company that starting selling antibodies door-to-door on a bike! David is the guest speaker at the launch session of the 2014/15 Enterprise Tuesday series on 4 November at the University of Cambridge's Department of Engineering. He will focus on telling the Abcam story but also look at other billion dollar companies that have come out of Cambridge. It's a good opportunity for those working in or contemplating a future in entrepreneurship to learn more about growing successful businesses. Read more about David Cleevely » http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/programme/speakers/cleevelyd.html Find out more about Abcam » http://www.abcam.com/ Without passion you cannot succeed! Listen to this podcast with Dr David Cleevely » http://www.sms.cam.ac.uk/media/1122496 Recognising opportunities … Watch video of Dr David Cleevely and Dr Andy Richards here » http://www.sms.cam.ac.uk/media/726139 Enterprise Tuesday is a series of FREE evening lectures and networking sessions delivered by the Centre for Entrepreneurial Learning (CfEL) which take place from November to the end of February in Cambridge. The programme aims to introduce participants to the world of business, as well as to encourage and inspire individuals to pursue their entrepreneurial ambition. It is the most popular non-assessed programme within the University and the model has been adopted by numerous other academic institutions as well as corporations. Enterprise Tuesday is open to all University of Cambridge staff and students, members of other universities and the local business community. The series is particularly relevant for postgraduate students considering future career paths, those exploring entrepreneurial opportunities and looking to build high quality networks with experts and practitioners. Find out more about Enterprise Tuesday at http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/index.html

Dr David Cleevely knows a thing or two about building businesses. A serial entrepreneur and investor, he has worked at the heart of the Cambridge Cluster on numerous ventures including telecoms consultancy Analysys, web based antibody company Abcam (ABC.L); and G femto base station company, 3WayNetworks. Abcam, which he co-founded in 1998 and was Chairman of until 2009, currently has a $1.5bn valuation - not bad for a company that starting selling antibodies door-to-door on a bike! David is the guest speaker at the launch session of the 2014/15 Enterprise Tuesday series on 4 November at the University of Cambridge's Department of Engineering. He will focus on telling the Abcam story but also look at other billion dollar companies that have come out of Cambridge. It's a good opportunity for those working in or contemplating a future in entrepreneurship to learn more about growing successful businesses. Read more about David Cleevely » http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/programme/speakers/cleevelyd.html Find out more about Abcam » http://www.abcam.com/ Without passion you cannot succeed! Listen to this podcast with Dr David Cleevely » http://www.sms.cam.ac.uk/media/1122496 Recognising opportunities … Watch video of Dr David Cleevely and Dr Andy Richards here » http://www.sms.cam.ac.uk/media/726139 Enterprise Tuesday is a series of FREE evening lectures and networking sessions delivered by the Centre for Entrepreneurial Learning (CfEL) which take place from November to the end of February in Cambridge. The programme aims to introduce participants to the world of business, as well as to encourage and inspire individuals to pursue their entrepreneurial ambition. It is the most popular non-assessed programme within the University and the model has been adopted by numerous other academic institutions as well as corporations. Enterprise Tuesday is open to all University of Cambridge staff and students, members of other universities and the local business community. The series is particularly relevant for postgraduate students considering future career paths, those exploring entrepreneurial opportunities and looking to build high quality networks with experts and practitioners. Find out more about Enterprise Tuesday at http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/index.html

A pitch is one thing, but what you're really looking for in an entrepreneur is passion, drive and that ability to think like an entrepreneur. But this doesn't mean being an overt risk taker. On average the entrepreneur is only slightly more risk adverse than most, says Dr David Cleevely, technology entrepreneur. But what they do have is an overwhelming sense that they can influence events, an unwavering inner conviction and an ability to adapt and evolve ideas.

A pitch is one thing, but what you're really looking for in an entrepreneur is passion, drive and that ability to think like an entrepreneur. But this doesn't mean being an overt risk taker. On average the entrepreneur is only slightly more risk adverse than most, says Dr David Cleevely, technology entrepreneur. But what they do have is an overwhelming sense that they can influence events, an unwavering inner conviction and an ability to adapt and evolve ideas.

The Massachusetts Innovation Economy Partnership Mission 2011, led by the State’s Governor Deval Patrick, was on a visit to Cambridge as part of a 10-day international tour. This is a recoding of Governor Patrick's address on the desire to form new research and business collaborations.